MedKoo Cat#: 471207 | Name: PI-103 HCl
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

PI-103 HCl is a potent, cell-permeable, ATP-competitive inhibitor of phosphatidylinositol 3-kinase (PI3K) family members with selectivity toward DNA-PK, PI3K (p110α), and mTOR.

Chemical Structure

PI-103 HCl
PI-103 HCl
CAS#371935-79-4 (HCl)

Theoretical Analysis

MedKoo Cat#: 471207

Name: PI-103 HCl

CAS#: 371935-79-4 (HCl)

Chemical Formula: C19H17ClN4O3

Exact Mass: 0.0000

Molecular Weight: 384.82

Elemental Analysis: C, 59.30; H, 4.45; Cl, 9.21; N, 14.56; O, 12.47

Price and Availability

Size Price Availability Quantity
10mg USD 375.00 2 Weeks
50mg USD 775.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
371935-74-9 (free base); 371935-79-4 (HCl)
Synonym
PI-103 HCl; PI103 HCl; PI 103 HCl; PI-103 hydrochloride
IUPAC/Chemical Name
3-(4-morpholinopyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)phenol hydrochloride
InChi Key
XSQMYBFFYPTMFE-UHFFFAOYSA-N
InChi Code
InChI=1S/C19H16N4O3.ClH/c24-13-4-1-3-12(11-13)17-21-15-14-5-2-6-20-19(14)26-16(15)18(22-17)23-7-9-25-10-8-23;/h1-6,11,24H,7-10H2;1H
SMILES Code
OC1=CC=CC(C2=NC(N3CCOCC3)=C(OC4=NC=CC=C45)C5=N2)=C1.[H]Cl
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 384.82 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Toulany M, Minjgee M, Saki M, Holler M, Meier F, Eicheler W, Rodemann HP. ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition. Cancer Biol Ther. 2014 Mar 1;15(3):317-28. doi: 10.4161/cbt.27311. Epub 2013 Dec 9. PMID: 24351425; PMCID: PMC3974833. 2: Xing WJ, Zou Y, Han QL, Dong YC, Deng ZL, Lv XH, Jiang T, Ren H. Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors. Clin Exp Pharmacol Physiol. 2013 Jan;40(1):13-21. doi: 10.1111/1440-1681.12026. PMID: 23110505. 3: Donev IS, Wang W, Yamada T, Li Q, Takeuchi S, Matsumoto K, Yamori T, Nishioka Y, Sone S, Yano S. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. Clin Cancer Res. 2011 Apr 15;17(8):2260-9. doi: 10.1158/1078-0432.CCR-10-1993. Epub 2011 Jan 10. PMID: 21220474. 4: Fan QW, Cheng CK, Nicolaides TP, Hackett CS, Knight ZA, Shokat KM, Weiss WA. A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res. 2007 Sep 1;67(17):7960-5. doi: 10.1158/0008-5472.CAN-07-2154. PMID: 17804702; PMCID: PMC2597547.